Cardiopulmonary

Cardiovascular disease is the world’s number one killer and a significant driver of healthcare costs. Additionally, the five-year survival rate remains poor for about 50% of patients with pulmonary hypertension—escalating the urgent need for transformative medicines.

In collaboration with Bristol Myers Squibb, the Librexia program is the most comprehensive factor XIa inhibitor clinical development program to date, enrolling nearly 50,000 patients in three Phase 3 studies, including event reduction in acute coronary syndrome, stroke prevention in atrial fibrillation and stroke prevention after an acute ischemic stroke or high-risk transient ischemic attack.

The Phase 3 UNISUS trial, the first-ever head-to-head study in PAH, is evaluating our investigational endothelin receptor antagonist in prolonging the time to the first clinical events committee-adjudicated morbidity or mortality event in participants with symptomatic PAH.